Radiopharm Theranostics revealed the results of a clinical study of its cutting-edge imaging agent, 68Ga-RAD 301 on 44 pancreatic cancer patients – using its the biggest cohort yet – which delivered strong results. Importantly, the visual response was excellent with a high tumour-to-background ratio and no adverse events were recorded, which, according to the company, suggests RAD301 is a suitable and safe diagnostic agent for imaging αvβ6-protein expression in pancreatic cancer.
